Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, Jennifer H. Yearley et al.|Clinical Cancer Research|2015Cited by 799
Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.Amita Patnaik, M. Lehnert, Soonmo Peter Kang et al.|Journal of Clinical Oncology|2012Cited by 82
Figure S1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0
Supplementary Tables S1-2, Figure 1 from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0
Data from Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid TumorsAmita Patnaik, Anthony W. Tolcher, S. Peter Kang et al.|Unknown|2023Cited by 0